Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs
Open Access
- 14 August 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Abstract
Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration.Keywords
All Related Versions
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01-AI145435-A1, R01-AI153349, R21- AI149760, K08-AI139371)
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01-HL131829)
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
This publication has 55 references indexed in Scilit:
- Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic ModelingClinical Pharmacokinetics, 2024
- Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitisInternational Journal of Antimicrobial Agents, 2023
- Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic ModelingClinical Pharmacokinetics, 2023
- Tuberculous meningitis: progress and remaining questionsThe Lancet Neurology, 2022
- Neurofilament light compared to neuron-specific enolase as a predictor of unfavourable outcome after out-of-hospital cardiac arrestResuscitation, 2022
- Radiosynthesis and Biodistribution of 18F-Linezolid in Mycobacterium tuberculosis-Infected Mice Using Positron Emission TomographyACS Infectious Diseases, 2020
- Pretomanid: First ApprovalDrugs, 2019
- Radiosynthesis and PET Bioimaging of 76Br-Bedaquiline in a Murine Model of TuberculosisACS Infectious Diseases, 2019
- Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV plus Population Is Not Related to Antiretroviral TherapyClinical Pharmacology & Therapeutics, 2018
- Cerebrospinal fluid concentrations of antituberculosis agents in adults and childrenTuberculosis, 2010